<DOC>
	<DOCNO>NCT00812357</DOCNO>
	<brief_summary>Descriptive pharmacoepidemiological study use Symbicort Turbuhaler treatment asthma France impact new therapeutic strategy compliance control asthma</brief_summary>
	<brief_title>Symbicort Usage Asthma Treatment Impact New Therapeutic Strategy Compliance Asthma Control France</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Asthmatic patient treat disease Symbicort Turbuhaler Patients monitor asthma doctor least 12 month Patients see outpatient care baseline visit Patients agree participate study Patients chronic low respiratory disease asthma Patients receive antiIgE agent last 4 month Patients receive desensitisation treatment outside maintenance phase Patients deem unable respond study linguistic cognitive reason</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Symbicort Turbuhaler</keyword>
	<keyword>asthma</keyword>
	<keyword>cohort study</keyword>
	<keyword>France</keyword>
</DOC>